Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

DARMSTADT, Germany and NEW YORK, Feb. 16, 2019 /PRNewswire/ -- JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression US FDA has granted Priority Review to BAVENCIO plus INLYTA for patients with...